Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | AOC2 | O75106 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18295383 | 0.97 | CA1 (0.54) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL31724915 | 0.88 | CA12 (0.52) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL28430727 | 0.88 | CA12 (0.52) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL17974300 | 0.85 | CA12 (0.54) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL18295353 | 0.85 | CA1 (0.64) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL18551719 | 0.85 | CA12 (0.53) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL17974302 | 0.84 | CA12 (0.53) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL3980344 | 0.84 | CA12 (0.52) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL24359015 | 0.83 | CA12 (0.52) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL6478753 | 0.83 | CA12 (0.55) | CA1CA2CA12CA9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | CA1 3776/4885CA2 2335/4885CA12 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.